Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer
VVD-214 targets Werner helicase (WRN), a synthetic lethal vulnerability in cancers with high microsatellite instability (MSI-high) or deficient mismatch repair (dMMR)
Global Phase Ib clinical study will evaluate VVD-214 in patients with previously treated MSI-high or dMMR colorectal cancer
Progress of VVD-214 demonstrates continued advancement of Vividion’s clinical development capabilities and the potential of its covalent-first chemoproteomics approach to unlock challenging drug targets
Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that the first patient has been dosed in a Phase Ib combination clinical trial evaluating VVD-214, an investigational oral inhibitor of Werner helicase (WRN). The study is evaluating VVD-214 in combination with bevacizumab in patients with microsatellite instability-high (MSI-high) or deficient mismatch repair (dMMR) colorectal cancer whose disease has progressed following prior lines of therapy.
